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Despite these potential advantages, there are draw-
backs to thrombolysis.3,4 Disadvantages include the poten-
tial for hemorrhagic complications, a small but significant
incidence of stroke, and renal dysfunction related to
repeated angiography. If used for the acutely threatened
limb, delayed reperfusion may lead to irreversible ischemia.
There is significant expense associated with the throm-
bolytic agent itself, the need for serial angiography, and
patient surveillance, which often involves an intensive care
unit (ICU) or a step-down setting.5 Furthermore, surgical
intervention is frequently required. Despite the perceived
“less invasive” nature of this therapy, major morbidity and
mortality can often accompany thrombolysis.
Currently, there are a number of reports from individ-
ual centers and three large prospective randomized studies
in which the efficacy and safety of thrombolytic therapy
for lower extremity ischemia have been addressed. With
these multiple studies, one might anticipate a better defi-
nition of the role of thrombolysis in lower extremity
ischemia. However, the findings of the various trials are
conflicting, and each has its limitations. In all of these
studies, enrollment included patients with thrombosed
bypass grafts and native arteries. In several of these trials
amputation-free survival was used as the primary end
point with no information available about whether
patients had resolution of rest pain, necrosis, or healing of
their ulcerations. End points of only 6 months (eg, in
TOPAS [Thrombolysis or Peripheral Arterial Surgery])
Catheter-directed thrombolysis is a commonly used
alternative to surgery in the initial management of acute
arterial occlusive disease affecting the lower extremities.
The precise indications for thrombolysis are vaguely
defined and have been broadened by many to include
patients presenting with prolonged ischemic symptoms.1,2
Thrombolysis offers several potential advantages when
compared with the surgical alternatives. It may help dis-
solve platelet-fibrin aggregates in the microcirculation and
thrombi in collateral vessels. More gradual reperfusion
may avert the sudden release of anaerobic metabolites into
the systemic circulation and thus reduce the risk of reper-
fusion or compartment syndrome. Thrombolysis exposes
underlying arterial disease, which can often be treated
with less extensive interventions.
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Introduction: Intra-arterial thrombolysis is commonly used as the initial treatment of acute or subacute lower extrem-
ity ischemia.
Methods: To evaluate the efficacy and cost of thrombolysis, we retrospectively analyzed 100 consecutive cases (87
patients) in which intra-arterial lysis (urokinase) was used as the initial treatment for native arterial lower extremity
occlusive disease. The mean age of patients was 67 years, 57% of the patients were male, and preexisting peripheral vas-
cular disease was present in 74%. Presenting symptoms were limb-threatening ischemia (53%) and claudication (47%).
Acute symptoms (< 2 weeks’ duration) were present in 48%.
Results: The 30-day morbidity rate was 31%, and four patients died. Complications were significant bleeding (23%),
ischemic stroke (1%), and renal failure with (2%) and without (2%) dialysis. Concomitant angioplasty was performed
in 63%. Complete or significant lysis as demonstrated with angiography was achieved in 75% of iliac, 58% of
femoropopliteal, and 41% of crural vessels (P < .001). Within 30 days of lysis, 9% of patients underwent major ampu-
tation and 20% surgical revascularization (in 3 patients the extent of revascularization was lessened by the lytic ther-
apy). Amputation-free survival was 83% and 75% at 6 months and 2 years, respectively. Relief of ischemia (defined as
relief of claudication or limb salvage without major surgical intervention) was achieved in only 70% and 43% of patients
at 30 days and 2 years, respectively (Kaplan-Meier analysis; mean follow-up, 31 months). Patients with aortoiliac dis-
ease had significantly better outcomes than those with infrainguinal disease (P = .03). Duration or type of presenting
symptoms did not predict outcome. The cost of the initial hospitalization per patient for thrombolysis was $18,490.
Conclusion: Thrombolysis can be as or more costly than surgery and is associated with a suboptimal outcome in a sig-
nificant number of patients. These data lead us to caution against a uniform policy of initial thrombolysis for patients
who present with lower extremity ischemia. (J Vasc Surg 2001;33:1148-57.)
may favor less invasive and potentially less durable treat-
ments. Furthermore, the cost-effectiveness of thromboly-
sis as an alternative to surgery5-7 needs to be evaluated in
more detail.
Over the past 10 years at our institution, catheter-
directed thrombolysis has been liberally used as the initial
approach for the treatment of lower limb ischemia. In this
single-center study we review our experience with 100
consecutive cases of thrombolysis in patients who pre-
sented with native arterial occlusions. Survivals, limb sal-
vage, resolution of symptoms, and cost were evaluated to
better determine the efficacy of thrombolysis as the initial
therapy for patients with lower extremity ischemia.
METHODS
Patient selection. We retrospectively analyzed the
outcome and costs associated with 100 consecutive cases
of native artery thrombolysis performed for treatment of
lower extremity ischemia. We reviewed the hospital med-
ical records of all patients who underwent thrombolysis at
the New York Presbyterian Hospital–Cornell Medical
Center between January 1992 and September 1998.
Additional follow-up data were gathered during clinic vis-
its and from telephone interviews. The decision to use lysis
was left to the discretion of the vascular surgeon and inter-
ventional radiologist. No preestablished criteria were used
to select patients. We categorized patients according to
duration, type and severity of symptoms, and degree of
preexisting ischemia. The severity of acute and underlying
chronic ischemia was graded in accordance with guidelines
published by the Ad Hoc Committee on Reporting
Standards.8 The assessment of severity was based on each
patient’s medical history and physical findings, supple-
mented by findings on arterial Doppler scan. We excluded
patients who underwent thrombolysis for occluded bypass
grafts, dialysis shunts, upper extremity, or visceral arteries,
and those who underwent an endovascular procedure (eg,
angioplasty or stenting) as the initial approach to revascu-
larization before thrombolysis. Patients who had lower
extremity ischemia after an unrelated endovascular proce-
dure (eg, cardiac catheterization) were included in this
study. One 2-year-old patient who presented with a severe
burn injury complicated by leg ischemia was excluded.
Treatment protocol. In general, thrombolysis was
initiated at the time of diagnostic angiography, although
occasionally, thrombolytic therapy was performed as a sep-
arate procedure. During the period of this retrospective
review, thrombolytic procedures were performed by six
different vascular radiologists. The technique of throm-
bolysis used and the doses of urokinase administered were
at the discretion of the interventional radiologist. In gen-
eral, most occlusions were approached from the contralat-
eral femoral artery. The arterial segment was entered with
a shaped catheter and either a 0.035-inch Benson wire or
a Glidewire. The entire occluded segment was usually tra-
versed with at least the wire and frequently the catheter. A
bolus of urokinase (approximately 250,000 IU) was gen-
erally administered into the occluded segment followed by
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an infusion ranging from 60,000 to 120,000 IU/h (with
100,000 IU/h being the standard). Heparin was infused
concurrently during most procures at a concentration ade-
quate to maintain the partial thromboplastin time at 1.5-
2 × control. The patients were monitored in the
step-down portion of the surgical ICU. Follow-up arterio-
grams were performed at the discretion of the radiologist.
Once the underlying vascular anatomy was evaluated, pos-
sible endovascular or surgical treatment options were con-
sidered. At the conclusion of each procedure, the arterial
access sheath was removed with manual compression of
the puncture site after the effects of heparin were reversed.
Heparin was reinitiated 5 to 6 hours after sheath removal
when indicated.
Morbidity and outcome measures. The 30-day
morbidity was defined as any significant complication that
required additional therapy or monitoring or was associ-
ated with long-term sequelae. All morbidity and mortality
were ascribed to the patients in whom lysis was performed
regardless of whether a subsequent surgical procedure was
performed. Bleeding was considered a complication if it
necessitated transfusion, if it required a change in therapy,
or if it was associated with a fall in the hematocrit level of
at least 6 percentage points. Acute renal failure was
defined as a rise in the creatinine level above 1.5 mg/dL
in patients with a normal baseline creatinine level or a rise
in the creatinine level greater than 50% of the patient’s
baseline.
The outcome measures that were assessed included (1)
immediate anatomic success of lysis, (2) avoidance of a
surgical procedure that was not substantially less invasive
than what would have been necessary before the initiation
of lysis, (3) relief of ischemia, (4) limb salvage, and (5)
amputation-free survival. A limb was considered salvaged
if amputation above the transmetatarsal level (major
amputation) was not performed. Anatomic success was
assessed by reviewing the reports of completion arterio-
grams and graded as follows: complete resolution of clot,
recanalization with a residual filling defect, or no change.
Endovascular interventions that were performed for
underlying lesions revealed by successful thrombolysis
were considered part of the primary therapeutic approach.
In patients who subsequently underwent surgical revascu-
larization, all arteriogram reports were reviewed before
and after thrombolysis to assess if a simpler surgical proce-
dure could have been performed without thrombolysis.
Only surgical procedures that were not decreased in mag-
nitude by thrombolysis were considered failures of throm-
bolysis. To evaluate the durability of thrombolysis as the
initial treatment, we defined a compound outcome mea-
sure referred to as relief of ischemia. This variable indicates
the actuarial postprocedural time that a patient spends
without the need for a major amputation or repeat revas-
cularization and with improvement of the presenting
ischemic symptoms by at least one degree (according to
Rutherford et al8). This implied that ulcers showed signs
of healing, necrosis resolved, rest pain was alleviated, and
patients with claudication experienced an increase in their
walking distance. Limb loss was defined as an amputation
above the transmetatarsal level. Patients who died were
censored.
Predictive variables. We evaluated the effect of
patient characteristics and lesion-related variables on the
angiographic success rate, relief of ischemia, and the 30-
day morbidity/mortality rate. The following variables
were evaluated: the severity of ischemia (limb-threatening
ischemia vs claudication), duration of symptoms (> or <
14 days), level of obstruction, presumptive etiology
(embolization vs in situ thrombosis), patient’s age, the
presence of preexisting peripheral vascular disease (PVD),
diabetes mellitus, hypertension, renal disease, or any pre-
ceding endovascular procedure.
Cost calculation. We calculated the cost (not
charges) associated with hospitalization for thrombolysis,
including the cost of complications and additional surgical
procedures. This calculation was based on resource use
and included all fixed and variable costs associated with
thrombolysis. For each patient, the following variables
were evaluated: the length of stay in the step-down unit
($1500 per day),5 floor ($491 per day),5 angiography
suite ($519 per hour)9 and operating room ($870 hour),5
basic laboratory studies ($234), urokinase (Abbokinase;
$1.86 per 1000 units), contrast material (Reno-30; $0.82
per bottle), blood transfusions ($87 per unit), anesthesiol-
ogy reimbursement ($300 per hour), and computed
tomography scan ($818, including reimbursement for the
radiologist). The disposable interventional radiology
equipment included a 19-gauge double-wall needle ($9),
a Benson wire ($13), a 4F Omniflush catheter ($13), an
angled Glidewire ($35), Berenstein catheter ($13), a 6F
vascular sheath ($40), and a 5F pulse-spray catheter
($300). For angioplasty and stenting, an angioplasty bal-
loon ($295) and a metal stent ($1000), respectively, were
included. Physician reimbursement was gathered accord-
ing to the Medicare Part B fee schedule for the Current
Procedural Terminology codes related to each procedure.
Costs accrued from unrelated medical problems, such as
chronic hemodialysis, were not included. All costs were
actualized to 1999 US dollars according to the annual
Consumer Price Index.
Statistical analysis. Long-term outcome was deter-
mined with Kaplan-Meier analysis.10 The impact of patient
characteristics on this outcome was evaluated by means of
univariate analysis with the log-rank test.11 A t test of
independence and χ2 statistics were used to correlate
patient characteristics with nonactuarial outcome mea-
sures. Predictive variables with a significance of P less than
.2 as well as age and sex were entered into the multivari-
ate analysis with logistic regression and Cox regression
models.12 All statistical analyses were performed with an
SPSS 9.0 software package (SPSS Inc, Chicago, Ill).
RESULTS
Patient demographics and endovascular proce-
dures. We evaluated 100 consecutive cases in which
thrombolysis was used as the initial treatment for lower
extremity ischemia. All patients presented with native arte-
rial lesions. The demographic characteristics and present-
ing symptoms of the patient cohort are summarized in
Table I. Limb-threatening symptoms were present in 53%
of patients; claudication was the initial presentation in
47%. Ischemia was present less than 14 days before admis-
sion in 48%; 21% of patients presented within 48 hours of
the onset of symptoms. Fifty-two percent of patients were
treated for ischemic symptoms persisting longer than 2
weeks; in 20% symptoms were greater than 2 months in
duration. For patients with limb-threatening ischemia, the
duration of symptoms was usually less than 2 weeks (36 of
53 patients), whereas patients with claudication were more
likely to have symptoms that were longer than 2 weeks in
duration (35 vs 47 patients, P < .001). Follow-up was
available in 90% of patients, with a mean follow-up of 31
months.
Angiographic success and repeat procedures. The
vascular segments treated with thrombolysis included aor-
toiliac (16%), femoropopliteal (77%), and crural vessels
(51%). Concomitant angioplasty was performed in 63% of
cases including multiple angioplasties in 28% and stent
placement in 9% (Table II). Complete or significant lysis
as demonstrated with angiography was achieved in 73% of
iliac, 60% of femoropopliteal, and 40% of crural vessels;
angiographic failure of lysis occurred in 0% of iliac, 17% of
femoropopliteal, and 37% of crural vessels (P < .001).
Within 30 days of lysis, 29% of patients underwent a sur-
gical procedure (Table II). Nine percent of patients under-
went a major amputation, and 20% underwent surgical
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Table I. Baseline characteristics
Demographics
Age (mean, y) 67
Sex (% male) 57%
Presenting symptoms and signs
Severity
Limb-threatening ischemia 53%
Claudication 47%
Acuity
≤ 14 d 48%
> 14 d 52%
Risk factors and comorbid conditions
Hypertension 67%
Diabetes 34%
Coronary artery disease 51%
Atrial fibrillation 17%
Pulmonary disease 8%
Stroke 9%
Creatinine level > 1.5 mg/dL 20%
End-stage renal disease 5%
Cancer 12%
History of smoking 60%
Hypercoagulable state 7%
Recent arterial catheterization 12%
History of arterial embolization 5%
Preexisting peripheral vascular disease 74%
Preadmission medication
Aspirin 24%
Oral anticoagulants 22%
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cost. The influence of patient subgroups and complica-
tions on the hospital cost is shown in Table IV.
Predictive variables. Clinical and radiologic charac-
teristics and their association with relief of ischemia are
summarized in Table V. With the use of univariate analy-
sis, the presence of disease at the aortoiliac level was
indicative of greater chance of successful lysis compared
with disease in the infrainguinal level (P = .001). The vari-
ables predictive of relief of ischemia at 2 years were (1) the
absence of chronic renal disease (creatinine level ≤ 1.5
mg/dL; Fig 2, A; P = .03) and (2) isolated aortoiliac dis-
ease at the time of initial presentation (Fig 2, B; P = .03).
With multivariate analysis, only the absence of chronic
renal disease was predictive of a successful relief of
ischemia (P = .009). Because of the small number of
patients with isolated aortoiliac disease, no significance
was found for relief of ischemia by multivariate analysis. A
short (< 14 days) duration of ischemia before presentation
did not predict a favorable outcome (Fig 2, C). The sever-
ity of ischemia at presentation (claudication versus limb
threat) also did not influence success rate in terms of relief
of ischemia (Fig 2, D). Patients presenting with limb-
threatening ischemia did have a higher morbidity and
mortality (P = .02 by multivariate analysis).
DISCUSSION
The appropriate treatment for acute limb ischemia
remains controversial. Since the introduction of intra-arte-
rial thrombolysis, multiple studies, including three ran-
revascularization. Three of these revascularization proce-
dures (ie, 15%) were indicated for the treatment of lesions
revealed by successful lysis. One of these patients under-
went repair of a popliteal aneurysm; two other patients
underwent endarterectomy of isolated lesions in the iliac
and popliteal arteries.
Morbidity and mortality. The combined 30-day
morbidity and mortality rate was 31% as detailed in Table
III. Three patients died during their initial hospitalization,
and the fourth shortly after discharge (30-day mortality
rate, 4%). Two of the in-hospital deaths were related to
acute renal failure, one patient had ventricular tachycardia,
and the fourth was readmitted for pneumonia and respira-
tory failure.
Clinical outcome. A total of 11 patients underwent
amputation during the first year of follow-up. All of these
patients had presented initially with limb-threatening
ischemia. The limb-salvage rate at 1 year was 87% for all
patients and 76% for patients with critical limb ischemia.
The overall survival was 91%, 84%, and 66% at 6 months,
2 years, and 5 years, respectively. The amputation-free sur-
vivals for these same intervals were 83%, 75%, and 61%,
respectively (Fig 1). Relief of ischemia was achieved in 70%
of patients at 30 days. During follow-up this number
diminished to 61% and 43% at 6 months and 2 years,
respectively (Fig 2).
Costs. The major resources used for the average
patient undergoing thrombolysis are the following: length
of stay, 8.2 days; ICU stay 2.4 days; time in the angiogra-
phy suite, 6:39 hours; urokinase, 2,212,551 units; stents
(7/100 cases); disposable interventional radiology equip-
ment; and blood transfusions (43 units per 100 cases).
The average cost for the initial hospitalization for throm-
bolysis was $18,490 per patient. Urokinase accounted for
22% of this cost. The stay in the radiology suite and the
professional reimbursement for thrombolytic procedure
accounted for 18% and 11%, respectively. Postprocedural
observation in the ICU contributed with 19% to the total
Fig 1. Amputation-free survival. Kaplan-Meier percentages of
patients surviving without major amputation. Bars indicate SE.
Table II. Procedures performed within 30 days of lysis
Procedures No. of patients
Total 100
Lysis only 26
Angioplasty ± stenting 63
Surgical revascularization 20
Surgery was reduced by lysis 3
Surgery after failed lysis 17
Major amputation 9
Surgery for complications of lysis 3
Any open surgery 24
Table III. Morbidity and mortality
Any morbidity or mortality 31%
Mortality 4%
Any morbidity 29%
Any significant hemorrhage 23%
Significant groin hematoma 16%
Gastrointestinal or genitourinary hemorrhage 4%
Bleeding necessitating transfusion 13%
Bleeding necessitating operative/interventional repair 3%
Renal failure 4%
Renal failure necessitating dialysis 2%
Stroke 1%
Myocardial infarction 3%
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Fig 2. Relief of ischemia. Kaplan-Meier percentages of patients without major amputation or repeat revascularization and with contin-
uous improvement of ischemic symptoms during follow-up. Patients who died or were lost to follow-up were censored. Bars indicate
SE. A, All patients. B, Impact of chronic renal disease on relief of ischemia. C, Impact of vascular segment involved (isolated aortoiliac
disease vs infrainguinal involvement) on relief of ischemia. D, Impact of duration of deteriorating ischemia on relief of ischemia. 
E, Impact of severity of ischemia on relief of ischemia.
A
B C
D E
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 6 Korn et al 1153
Table IV. Hospital course and costs 
Length of ICU Angiography Urokinase 
Cost ($)
Groups stay (d) stay (d) suite (h) (1000 U) Mean 95% CI
Total 8.19 2.38 6:40 2213 $18,490 $16,680-$20,301
Severity
Limb-threatening 10.88 3.02 6:36 2457 $21,207 $18,622-$23,792
Claudication 5.21 1.66 6:45 1925 $15,219 $13,060-$17,377
Symptoms
< 2 wk 10.30 3.15 6:33 2647 $21,069 $18,217-$23,922
> 2 wk 6.29 1.67 6:47 1796 $16,066 $15,403-$18,141
Complications*
Yes 13.32 3.90 6:54 2571 $23,625 $20,108-$27,141
No 5.97 1.71 6:35 2055 $16,301 $14,406-$18,195
*Complications include any hemorrhage with a drop in the hematocrit level by at least 6 points or requiring transfusion, myocardial infarction, stroke, renal
failure, and death at 30 days.
Table V. Predictive variables, morbidity and mortality rate, 2-year outcome
Morbidity/mortality (30 d) Relief of ischemia (2 y)
Variable No. % P value* % P value†
Severity
Claudication 47 18% 45%
Limb-threatening 53 40% .022‡ 42% > .2
Duration of symptom
≤ 14 d 48 32% 43%
> 14 d 52 28% > .2 43% > .2
Preexisting PVD
Present 74 25% 44%
Absent 26 42% .11 43% > .2
Level of obstruction
Isolated aortoiliac 6 20% 100% 
Infrainguinal 94 30% > .2 40% .03
Diabetes mellitus
Present 35 32% 43% 
Absent 65 29% > .2 44% > .2
Creatinine level
> 1.5 mg/dL 14 36% 20% 
≤ 1.5 mg/dL 86 29% > .2 47% .003‡
Presumptive etiology
Embolization 31 35% 45%
In situ thrombosis 69 27% > .2 43% > .2
Age
≥ 65 y 42 34% 43% 
< 65 y 48 23% > .2 43% > .2
Hypertension
Present 63 29% 52% 
Absent 37 32% > .2 29% .12
Preceding endovascular procedure
Yes 12 33% 71%
No 88 29% > .2 40% > .2
*Univariate analysis with χ2 test.
†Univariate analysis with log-rank test.
‡Statistically significant (P < .05) with multivariate Cox-analysis.
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domized trials, have been performed to evaluate its effi-
cacy. In the Rochester trial, 114 patients presenting with
worsening or new onset lower extremity ischemia of less
than 1-week duration were randomized to either catheter-
directed thrombolysis or surgery.13 Although the limb sal-
vage rate was similar between groups, patients treated with
urokinase had improved survival because of fewer periop-
erative cardiopulmonary complications. In the STILE
(Surgery versus Thrombolysis for Ischemia of the Lower
Extremity) trial, 393 patients presenting with limb threat
or claudication of up to 6 months’ duration were ran-
domized to thrombolysis or surgery.14 In the first iteration
of this trial published in 1994, the authors found, in
patients with symptoms persisting less than 14 days, a
lower amputation rate for thrombolysis compared with
surgery. However, initial surgery was superior to throm-
bolysis in patients with more prolonged symptoms.14 Data
from this study were reported again in 1996 by Weaver et
al.15 In this analysis, the authors focused only on those
patients who had lysis of native arterial lesions, a subpop-
ulation identical to the cohort in our study. In this reanaly-
sis, they found initial surgery to be superior to lysis for all
patients, regardless of the duration of ischemia. In the
TOPAS trial, only patients with symptoms persisting less
than 14 days were allowed to enroll.16 A total of 544
patients were accrued from 113 centers over a period of
16 months. The authors used amputation-free survival at
6 months as the end point and found an equivalent out-
come for surgery and lysis. The authors argued that with
equivalent outcomes, thrombolysis should be the pre-
ferred initial intervention because of its “less invasive”
nature. Of significance, two thirds of the patients in the
thrombolysis cohort had a surgical intervention within 6
months of randomization. In all three trials, recruitment
included both patients with native artery occlusion as well
as thrombosis of vein or prosthetic bypass grafts.
The outcome measures used to judge success of
thrombolysis have varied considerably; this variation may
account for the discrepant findings of the various studies.
We chose relief of ischemia as our primary outcome mea-
sure, defined as a sustained improvement of the patient’s
ischemic symptoms after thrombolysis without the need
for subsequent interventions. With this definition, throm-
bolysis was successful in only 70%, 53%, and 43% of our
patients at 30 days, 1 year, and 2 years, respectively. In the
STILE trial a similar end point was used (although these
investigators also included 30-day mortality and morbidity
rate as an adverse outcome, in addition to ongoing or
recurrent ischemia).14,15 With this composite clinical out-
come measure, thrombolysis for native arterial disease was
successful in only 29% of patients at 1 year.15 The primary
outcome measure used in the TOPAS trial was amputa-
tion-free survival. Patients in the TOPAS trial could have
“favorable” outcomes even if they had recurrent disease
that was successfully treated with surgical revasculariza-
tion. Moreover, with amputation and death as the only
outcomes, patients with recurrent or residual ulcers, rest
pain, or necrosis not yet resulting in amputation would be
counted as clinical successes. Even from our own data, we
observed a dramatic difference at 2 years between relief of
ischemia and amputation-free survival (43% and 75%,
respectively). Even though more than half of the patients
in our study were treated for claudication, the outcome of
these patients is less likely to be amputation. Thus, the
favorable results of the TOPAS trial and the less favorable
findings of the STILE trial may be related solely to the
measures used to define success.
The issue of whether patients presenting with claudica-
tion should be treated with initial thrombolysis has not
been clearly defined. In this study, nearly half of the
patients were treated for new-onset or worsening claudica-
tion. Our findings suggest that in general, thrombolysis
should not be used as the initial treatment for these
patients. The 30-day mortality and morbidity rate in this
subgroup of patients was 18%. Moreover at 2 years, only
43% of patients had relief of their symptoms. These results
compare unfavorably with most reports of femoropopliteal
bypass graft for claudication.17,18 Most patients treated for
claudication had symptoms persisting longer than 14 days.
The question remains as to whether patients with recent
onset of claudication might achieve a more substantial ben-
efit from thrombolysis (there were only 12 such patients in
our series). Suggs et al,19 in a small cohort of eight patients
with new-onset claudication, achieved successful lysis and
relief of symptoms without complication in all. In contrast,
Brainthwaite et al20 recently evaluated the short-term out-
come of thrombolysis for a cohort of 56 patients with the
recent onset claudication. These authors found that in
patients with native arterial occlusions, there was relief of
symptoms in 68% at 30 days with a rate of major amputa-
tion of 8% and a mortality rate of 14%. We conclude from
the findings of these authors and our own data that
although not contraindicated, thrombolysis should be used
cautiously in patients in whom claudication is the only
manifestation of lower extremity ischemia.
In predicting the success of lysis much attention has
focused on the duration of ischemia and its relationship to
outcome. Logically, one might anticipate that “fresh” clot
might respond to lysis more favorably than old. This con-
cept was reinforced by the initial findings of the STILE
trial.14 Patients with symptoms of less than 14 days, when
treated with thrombolysis, had lower amputation rates,
shorter hospital stays, and improved amputation-free sur-
vival at 6 months when compared with patients with pro-
longed symptoms. These findings pertained to the entire
population of patients enrolled in the STILE trial, which
included patients with thrombosis of native arterial lesions
and patients with clotted bypass grafts. When a post hoc
analysis of these same data was performed selecting only
those patients treated for native artery occlusion, there
was no advantage of lysis over surgery in patients with
symptoms persisting less than 14 days.15 The authors con-
cluded that the duration of symptoms is an important fac-
tor when considering lysis for occluded bypass grafts but
not for native arterial lesions. Our findings support their
conclusion. At 2 years relief of ischemia was approximately
43% in all patients regardless of the duration of their pre-
senting symptoms.
Our data suggest that lysis is a reasonable initial
approach for the small subset of patients who present with
isolated aortoiliac occlusion. Both the radiologic clearance
of thrombus and the clinical outcome at 2 years were more
favorable in patients with aortoiliac versus infrainguinal
lesions. These findings are supported by those of the
STILE trial where the outcome of lysis of aortoiliac lesions
was superior to that of femoropopliteal disease.15
The costs associated with thrombolysis deserve con-
sideration. Our data and the findings of other investigators
demonstrate that the cost of the initial hospitalization for
lower extremity thrombolysis is either equivalent or
greater than that for infrainguinal bypass graft. We have
derived the average hospital cost (not charge) of throm-
bolysis for these 100 cases using a resource utilization
analysis. We found the average cost of thrombolysis per
patient to be $18,490. Most of this cost was related to the
radiologic intervention (eg, angiography suite, techni-
cians, urokinase). These costs are in the range of what has
been reported for infrainguinal surgical revascularization.
Jansen et al21 reported an average cost of $22,096 for
femoropopliteal bypass graft and $22,096 for femorotibial
bypass graft (actualized to 1999 US dollars). Thus, the
cost of thrombolysis, although not inordinate, is approxi-
mately the cost of open surgery. Ouriel et al7 found in an
analysis of the Rochester trial, total treatment costs of
$22,171 for the thrombolytic group and $19,775 for the
operative group. In a retrospective analysis, Hoch et al6
reported hospital and professional patient charges for 24
patients and found that they were higher with thromboly-
sis ($45,171) than with surgery ($24,898). Dacey et al22
found comparable charges for thrombolytic and surgical
procedures, but a substantially higher “charge per success-
ful revascularization” for thrombolysis.
Proponents of lysis argue that even though a substan-
tial proportion of patients treated with initial lysis will
eventually require surgery (2/3 at 6 months in the TOPAS
trial), some will not, and in others the magnitude of the
surgical procedure may be diminished.16 This logic fails
when issues related to cost are considered. The expense
associated with two interventions is required for patients
receiving lysis, whereas the expense of only one interven-
tion is necessary in patients receiving initial surgery.
Although this simplistic analysis does not take into account
the types of surgical procedures that are performed
(thrombolysis may reduce the magnitude of surgical inter-
ventions) or the potential economy if lysis and surgery are
performed during the same hospitalization, the fact
remains that many patients will have multiple interven-
tions. This raises the possibility that a strategy of initial lysis
may be significantly more costly than a strategy of initial
surgery. We have previously performed a cost-effectiveness
analysis that was based on TOPAS trial data with a Markov
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decision analytic model.5 We found initial surgery to be
substantially more cost-effective than thrombolysis.
Many proponents contend that thrombolysis is “less
invasive” and as such is a more appealing alternative than
surgery.16,23 Although thrombolysis does not require a
general or regional anesthetic, it can be associated with a
substantial number of local and systemic complications. In
this study the mortality rate was 4%, and the rate of major
complication was 29%. Major complications included
hemorrhage (with a drop in the hematocrit level of more
than 5% points or requiring transfusion or surgery; 23%),
renal failure with (2%) or without (2%) dialysis, and stroke
(1%). In the TOPAS trial, mortality rates in the surgical
and urokinase groups were 5.9% and 8.8%, respectively.16
Major hemorrhage was reported in 12.5% of the urokinase
cohort compared with 5.5% of those patients receiving
surgery, and intracranial hemorrhage occurred in 1.6% of
patients treated with urokinase.16 Thus, from the stand-
point of mortality and morbidity it is not clear that throm-
bolysis is “less invasive” than surgery.
This retrospective study is limited in several respects.
Most important, there is no randomized surgical cohort
for comparison. Patients requiring lysis are often selected
because of their significant comorbidities and urgent pres-
entation; as such, there is selection bias, making compari-
son to a standard surgical series difficult. We also were
unable to determine the number of patients in whom
thrombolysis was not performed because of a failure to
gain access to the thrombosed arterial segment. In the
STILE trial, 28% of patients who were randomized to lysis
did not receive the thrombolytic agent because of failure
of catheter placement.14 The fact that primary failures of
thrombolysis of this nature were not included in our
analysis may have led to an artificial increase in the calcu-
lated success of lysis. Finally, in the United States, uroki-
nase was recently removed from the market and has been
replaced at most centers with tissue plasminogen activator.
In this study, all patients were treated with urokinase
although in several trials no substantial difference in either
efficacy or safety has been found between urokinase and
tissue plasminogen activator.14,24,25
Despite these limitations, our series does focus on only
those patients who have native arterial thrombosis.
Moreover, these patients were accrued in a consecutive
manner, diminishing the potential for selection bias. In
general, our data corroborate the findings of the STILE
trial. Thrombolysis for native lower extremity arterial dis-
ease is associated with significant morbidity and mortality
and a substantial rate of persistent or recurrent ischemia.
With the exception of patients presenting with aortoiliac
thrombus or normal renal function, we could not identify
a subset of patients with more favorable outcomes. Our
findings strongly argue against a standard policy of initial
thrombolysis for all patients who present with lower
extremity thrombosis. Thrombolysis, however, should
remain one of the available tools in the armamentaria of
physicians who treat peripheral vascular disease.
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DISCUSSION
Dr Robert Patterson. (Providence, RI). I was amazed at the
number of patients you had who had primary thrombolysis for
claudication, which I think is perhaps a little more aggressive than
I would be in my own practice, and lumping them together I have
trouble figuring what the complication rate is in that particular
subset. I mean, I consider that a relatively benign disease, and if
you are having a high incidence of limb loss and other complica-
tions, bleeding, stroke, I think that might be an overly aggressive
approach to this disease. Then it further makes it hard for me to
pick out those patients whom I might consider in my own prac-
tice with more acute limb-threatening ischemia and what their
actual outcomes were. Could you break it down a little bit more?
Dr Peter Korn. We agree that, during the period of study,
thrombolysis was performed very liberally in patients presenting
with claudication, which certainly is a rather aggressive approach
for claudicants. Fortunately, the overall outcome in this subset of
patients with more benign disease was better compared with the
outcome in patients with limb-threatening ischemia. None of the
patients who presented with claudication needed an amputation.
The hospital cost was lower for patients with claudication.
However, when we looked at the clinical success rate with respect
to relief of ischemia, the outcome was not significantly different
compared with patients with limb-threatening ischemia. With
stringent criteria for clinical success, which included no persistent
or recurrent ischemia and no subsequent procedures (unless
decreased in invasiveness), only 45% of claudicants had ongoing
relief of ischemia at 2 years.
With regard to duration of ischemia, we could not identify
any difference in the outcome whether patients presented with
deterioration of less or more than 2 weeks’ duration. We also
looked at the patients who presented within 2 days and those who
presented with ischemia that lasted longer than 2 months. Again,
there was no significant difference with respect to relief of
ischemia. It should be pointed out that similar results were
obtained in the subset analysis of the STILE trial, which was
restricted to patients with native artery disease. Here the finding
of the original trial where patients with ischemia of less than 14
days’ duration fare better than patients with longer duration
could not be confirmed.
Dr Frank Pomposelli. (Boston, Mass). I enjoyed your pres-
entation. I compliment you for tackling such a difficult topic. I
would be the first one in this room to admit that I still do not
have a clear idea when is the appropriate time to use thromboly-
sis. I agree with Dr Patterson that thrombolysis has a limited role
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in the treatment of claudication, perhaps except when you are
planning an iliac angioplasty and there is some thrombosis present
either before or after angioplasty. Could you give us some idea
when you think this is really useful? The one group of patients in
my practice where I have found this useful is someone who comes
in with an acutely threatened or perhaps even chronically threat-
ened limb and a good-quality arteriogram demonstrates no defin-
able runoff vessels. If a course of thrombolysis opens a distal
vessel, you persist until you see what appears to be a reasonably
good outflow target and then perform a suitable arterial recon-
struction. Have you had any experience with that group of
patients, and do you think that is a good indication?
Dr Korn. This is a very good question. I agree with Dr
Pomposelli regarding the indications of thrombolysis. The data
obtained during the last years at our institution clearly represent
a rather aggressive approach in using thrombolysis. After doing
this retrospective analysis I feel that overall, we should be more
cautious when considering thrombolysis. However, a scenario
where lysis may help to restore patent outflow vessels as potential
targets for bypass certainly seems appealing. Unfortunately, it is
difficult to obtain hard data to support such a contention. One
problem with most of the trials addressing such issues, including
our trial, is that the patient population and the presentation in
terms of clinical and angiographic findings are exceptionally com-
plex. This fact makes it hard to appreciate well-defined subgroups
for statistical analysis, as multiple confounding factors may inter-
fere. At this point I feel that, in such a scenario, thrombolysis
should be used at the discretion of an experienced vascular sur-
geon and interventional radiologist.
Dr Thomas F. O’Donnell, Jr. (Boston, Mass). We have just
heard a very interesting paper, which raises two questions for me.
The first, what technique and dose schedule did you use? Was it
high- or low-dose urokinase? What was the duration of infusion?
As we have shown, duration of lytic infusion will drive up not only
drug cost but also the cost of ICU and radiology suite utilization.
After how many hours of infusion did your radiologist or your
experienced vascular surgeons decide to say enough is enough
and recommend cessation of lytic therapy?
The second question reflects on Dr Pomposelli’s point: did
you rely on reports or did you actually analyze the initial arterio-
grams yourselves to determine the degree of runoff, especially if
there was none evident, and then repeat the arteriographic analy-
sis after urokinase infusion? A target vessel might have then been
visualized particularly in those very ischemic limbs.
Thank you.
Dr Korn. The dosages used and the duration of treatment in
the individual patient were at the discretion of the intervention-
ists and surgeon, and showed considerable variation from case to
case. Likewise, the decision to abort thrombolysis was based on
the individual findings. Generally, treatment protocols similar to
those described in TOPAS or STILE were used. The average dose
of urokinase was about 2 million units and the average duration
of infusion about 2 days, with monitoring in the step-down unit
for the treatment period. The duration of infusion as predictor of
success was not analyzed statistically, as patients with longer treat-
ment duration typically had more extensive disease at presenta-
tion. In selected patients, especially when multilevel disease was
present, some additional benefit was noted even after the second
day of lysis. However, considering the increased risk of complica-
tions and also the costs of monitoring, I feel that a lower thresh-
old to pursue alternative means of revascularization should be
utilized.
With respect to the second question, we did not analyze the
original arteriograms. This study was based on the radiology
reports, which provided very detailed data. To define the role of
thrombolysis as adjunct to surgery, we retrospectively looked at
all patients who underwent surgery and evaluated the type of pro-
cedure that was done with respect to the outcome of lysis prior to
the procedure. Most patients who underwent surgery underwent
surgery for unsuccessful lysis. We defined three patients who
underwent surgery, where we felt that thrombolysis had helped as
adjunct to surgery. These were two patients with popliteal disease,
one with an aneurysm, who underwent exclusion of the
aneurysm, and one with a calcified stenosis who underwent
endarterectomy at this stenosis. The third patient had an iliac
endarterectomy after lysis revealed a dissection in this region. In
these cases the outcome of thrombolysis offered a limited surgi-
cal approach to be pursued. We could not identify patients in our
cohort, where thrombolysis provided recanalization of target ves-
sels for subsequent bypass.
Dr K. Craig Kent. (New York, NY). I apologize for breaking
the golden rule, which is that you are not supposed to comment
on your own paper. But I did want to respond to Dr Pomposelli
and Dr Patterson and make sure that Peter and I both let you
know what conclusions we have derived from this study. We do
not feel that thrombolysis should be used in patients with claudi-
cation. Although there were not a significant number of major
complications that occurred in this subgroup, a success at 2 years
of only 40% in terms of resolution of symptoms is insufficient to
warrant the routine use of thrombolysis for claudicants.
